RAN to collaborate with Celgene on cancer therapeutics development

The RAN has recently signed a 3-year $25M agreement with the Celgene Corporation to develop next-generation, antibody-based cancer therapies with the option to enter into future license agreements. Collaboration will focus on novel high value cancer targets. Besides supporting the high throughput antibody generating pipelines, this agreement will enable setting up robotics for a battery of state of the art cell based assays. The capacity that can be achieved with regard to antibody generation and target validation is unmatched by any similar facility in the world. 

Offical press release


University of Toronto  UCSF  The University of Chicago  QB3  Chicago Biomedical Consortium